Brief: Epigenomics: ADMIT study results published in journal Cancer Treatment and Research Communications
11/01/2017 07:33
Jan 11 (Reuters) - Epigenomics AG ECXn.DE :
* Journal of "Cancer Treatment and Research Communications"
publishes results of study with blood test Epi proColon
* Study results confirm that a blood-based colorectal cancer
screening test has potential to increase participation in
colorectal cancer screening compared to a fecal test
Source text for Eikon: ID:nEQbbTxq6
Further company coverage: ECXn.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 722 0920;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns